Biogen pushing tau drug forward despite Alzheimer’s study failure

One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the strength of the biomarker and efficacy data” seen in a Phase 2 trial.

giovedì 14 maggio 2026 New tab

605 words~3 min read

An article from

Dive Brief

One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the strength of the biomarker and efficacy data” seen in a Phase 2 trial.

Published May 14, 2026

Biogen pushing tau drug forward despite Alzheimer’s study failure

Biogen pushing tau drug forward despite Alzheimer’s study failure

Other newsrooms on this story

Related reading

Biogen advances Alzheimer's drug to late-stage trial despite disappointing data

Updated: Biogen won’t be ‘impulsive’ with anti-tau Alzheimer’s drug

Biogen's tau-targeting Alzheimer's drug posts mixed results in mid-stage study

Closely watched experimental Parkinson’s drug fails key clinical trial

Biogen and Denali’s Parkinson’s candidate did not meet Phase 2b endpoints

Biogen Inc. (BIIB) Securities Fraud Investigation - Levi & Korsinsky

Other newsrooms on this story

Related reading

Biogen advances Alzheimer's drug to late-stage trial despite disappointing data

Updated: Biogen won’t be ‘impulsive’ with anti-tau Alzheimer’s drug

Biogen's tau-targeting Alzheimer's drug posts mixed results in mid-stage study

Closely watched experimental Parkinson’s drug fails key clinical trial

Biogen and Denali’s Parkinson’s candidate did not meet Phase 2b endpoints

Biogen Inc. (BIIB) Securities Fraud Investigation - Levi & Korsinsky